The objective of the present study was to identify the molecular and genetic risk factors responsible for the development of varicose veins in the small pelvis. Material and methods. The main study group was comprised of 20 female patients of the reproductive age (from 20 to 40 years) presenting with varicose vein disease. The control group consisted of 150 patients at the age from 20 to 45 years free from diseases of the lower extremities and the small pelvis. The exclusion criteria for both groups were the concomitant gynecological, urological, and oncological problems, pregnancy and the postpartum period (up to 6 months), and the experience of the surgical interventions in the preceding period (within 6 months before the inclusion in the study). All the participants in the study underwent genotyping of the allelic variants of the matrix metalloproteinase 1171 MMP-3 gene dupA (5A/6A) and the matrix metalloproteinase MMP-12 gene 82 A/G as well as of the allelic variants of the vascular endothelial growth factor gene VEGF-634 G/C. Results. The results of the present pilot case-control study give evidence that the carriage of the MMP-3 gene 5A/6A allelic polymorphism increases the risk of development of varicose veins in the small pelvis (OR=2.253; p=0.0182). Moreover, the carriers of the polymorphous C allele of the VEGF-634 G/C gene were found to be at enhanced risk of developing the same pathology (OR=4.344; p=0.00001). Conclusion. The study has demonstrated that the polymorphic variants of the ММР-3 and VEGF genes can be considered as the potential molecular-genetic predictors of varicose vein disease of the small pelvis and the dysplastic process in the inferior vena cava system. The data obtained on genetic polymorphism suggest the necessity of further studies for the improvement of elucidation of the risk of development of varicose veins in the small pelvis and the lower extremities.